Crinetics Pharmaceuticals

Forecast & Rating14 analysts currently cover Crinetics Pharmaceuticals, with about 14.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $82.50, about 1.4% downside from the current price of $83.65. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 46.3% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Crinetics Pharmaceuticals's outlook. Data as of Jul 17, 2026; for reference only and not investment advice.